Overview

A six-gene male tumor susceptibility panel is a germline genetic testing service that interrogates six cancer-predisposition genes from a peripheral blood sample. The test is intended for adult males with a personal or family history suggestive of hereditary cancer, particularly where the family pattern involves early-onset disease, multiple primary tumours, or rare cancer types that are characteristic of germline mutation carriers.

The power of a panel over single-gene testing lies in pathway coverage. Each of the six genes represents a distinct biological pathway for tumour suppression, and a single panel can therefore evaluate hereditary risk across prostate, colorectal, pancreatic, renal, melanoma and other cancer types that share genetic aetiology. The service is delivered through a laboratory that performs next-generation sequencing under CLIA or equivalent accreditation.

How the Six Pathways Are Read

The genes on a typical male tumor susceptibility panel map onto the canonical tumour-suppressor and DNA-repair pathways that underlie the most common hereditary cancer syndromes. DNA mismatch repair genes, for example, are interrogated because germline pathogenic variants in these genes underlie Lynch syndrome and confer elevated lifetime risk of colorectal, endometrial and other cancers in male carriers. Homologous recombination repair genes are read because germline variants in this pathway are associated with breast, prostate and pancreatic cancers.

Beyond these two pathways, the panel covers cell-cycle checkpoint genes, which when mutated disrupt the G1/S checkpoint and predispose to a range of solid tumours, and genes associated with familial melanoma and renal cancer syndromes. The intent is not to test every cancer-predisposition gene, but to cover the highest-yield six in a single assay for adult males.

From a laboratory workflow perspective, the panel begins with DNA extracted from the blood sample. Targeted capture or amplicon-based sequencing enriches the six gene regions, the sequencing reads are aligned to the human reference genome, and variants are called and annotated against curated databases of germline pathogenic variants. Per ACMG and NCCN guidance, variants are classified into five tiers: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign. Only the first two categories are typically returned as positive findings to the ordering clinician.

Clinical Use and Counselling

A positive finding on the panel has implications for the patient and for at-risk family members. Per NCCN genetic testing guidelines, the result should be communicated through a genetics professional who can advise on cascade testing of relatives, surveillance protocols, and risk-reducing strategies. The test itself is a susceptibility test, not a diagnostic test; a positive finding elevates the probability of future cancer but does not establish a current diagnosis.

FAQ

Q: Is this test diagnostic for cancer? A: No. It is a susceptibility test that identifies germline variants associated with elevated hereditary cancer risk, not a test for the presence of cancer.

Q: Why only six genes? A: The six genes cover the most evidence-based hereditary cancer pathways relevant to adult males. Larger panels exist but trade off higher yield against higher rates of variants of uncertain significance.

Q: How are variants of uncertain significance managed? A: Per ACMG standards, VUS results are not acted on clinically. They may be reclassified as evidence evolves, and the laboratory re-issues reports when reclassification occurs.

Q: Should relatives be tested after a positive finding? A: Yes. Per NCCN, cascade testing of at-risk relatives is recommended to identify other carriers in the family and to guide individualised surveillance.